Pharma firm settles at ARC Uxbridge

ARC has strengthened its Uxbridge cluster by signing European pharmaceuticals firm Norgine as the tenant at the second floor of Building 01.  The 10-year lease covers almost 24,000 sq ft of recently refurbished workspace. According to EG Radius data, the deal was signed at £38 per sq ft. The transformation of Building 01 has led to EPC A and BREEAM Very Good ratings and has been designed to create flexible spaces with a focus on wellbeing. New sustainable measures have also been introduced, including roof-mounted PV panels and air source heat pumps.  Other occupiers on the campus include Bristol Myers Squibb, Parexel, Daiichi Sankyo and Amgen. Norgine will also become part of ARC’s wider network of more than 100 life sciences organisations, such as Moderna, OMass Therapeutics and Barinthus Bio, which are developing novel therapeutics.  Andrew Davies, leasing director at ARC, said: “We welcome Norgine to ARC Uxbridge and to our wider life sciences cluster. Their decision to join us reflects the growing reputation of ARC as a hub for innovation and excellence in the life sciences sector. “With Norgine’s presence, we are enhancing the collaborative environment within our member community and paving the way for groundbreaking advancements in medical research and development.”